Brion L P, Soll R F
Pediatrics, Division of Neonatology, Albert Einstein College of Medicine and Montefiore Medical Center, Weiler Hospital Room 725, 1825 Eastchester Road, Bronx, NY 10461, USA.
Cochrane Database Syst Rev. 2000(2):CD001454. doi: 10.1002/14651858.CD001454.
Lung edema may complicate respiratory distress syndrome (RDS) in preterm infants.
The aim of this review was to assess the risks and benefits of diuretic administration in preterm infants with RDS.
We used the standard search method of the Cochrane Neonatal Review Group. We searched Medline, Embase and the Cochrane Controlled Trials Register from the Cochrane Library, using the following keywords:
We only included trials in which preterm infants with RDS and less than 5 days of age were randomly allocated to diuretic administration. Of those trials, we only included studies in which at least one of the following outcomes measures was evaluated: mortality, patent ductus arteriosus, hypovolemic shock, intraventricular hemorrhage, renal failure, duration of oxygen supplementation, duration of mechanical ventilation, need for oxygen supplementation at 28 days of life, oxygen supplementation at 36 weeks of postconceptional age (gestational age + postnatal age), length of stay, number of rehospitalizations during the first year of life, and neurodevelopmental outcome.
We used the standard method for the Cochrane Collaboration which is described in the Cochrane Collaboration Handbook. Two investigators extracted, assessed and coded separately all data for each study. Any disagreement was resolved by discussion.
Six studies met inclusion criteria. Studies available for this systematic review were all done before the current era of prenatal steroids, surfactant, indomethacin and fluid restriction. Furosemide administration had no long-term benefits. Furosemide-induced transient improvement in pulmonary function did not outweigh an increased risk for patent ductus arteriosus and for hemodynamic instability.
REVIEWER'S CONCLUSIONS: There are no current data to support routine diuretic administration in preterm infants with RDS. Elective administration of furosemide or any diuretic to any patient with RDS should be carefully weighed against the risk of precipitating hypovolemia. In addition, elective administration of furosemide should be weighed against the risk of developing a symptomatic patent ductus arteriosus.
肺水肿可能使早产儿呼吸窘迫综合征(RDS)复杂化。
本综述的目的是评估利尿剂用于患有RDS的早产儿的风险和益处。
我们采用了Cochrane新生儿综述小组的标准检索方法。我们使用以下关键词在Medline、Embase以及Cochrane图书馆的Cochrane对照试验注册库中进行检索:<呼吸窘迫综合征>和<利尿剂>。此外,我们检索了美国胸科学会和儿科学研究学会的摘要集。
我们仅纳入将年龄小于5天的患有RDS的早产儿随机分配接受利尿剂治疗的试验。在这些试验中,我们仅纳入至少评估了以下一项结局指标的研究:死亡率、动脉导管未闭、低血容量性休克、脑室内出血、肾衰竭、吸氧持续时间、机械通气持续时间、出生28天时的吸氧需求、孕龄36周(胎龄+出生后年龄)时的吸氧情况、住院时间、出生后第一年内再次住院的次数以及神经发育结局。
我们采用了Cochrane协作网的标准方法,该方法在《Cochrane协作网手册》中有描述。两名研究人员分别对每项研究的所有数据进行提取、评估和编码。任何分歧都通过讨论解决。
六项研究符合纳入标准。本次系统综述所纳入的研究均在当前使用产前类固醇、表面活性剂、吲哚美辛和液体限制的时代之前完成。使用呋塞米没有长期益处。呋塞米引起的肺功能短暂改善并未超过动脉导管未闭和血流动力学不稳定风险增加的影响。
目前没有数据支持对患有RDS的早产儿常规使用利尿剂。对于任何患有RDS的患者,选择性使用呋塞米或任何利尿剂时,应仔细权衡引发低血容量的风险。此外,选择性使用呋塞米时应权衡发生有症状动脉导管未闭的风险。